Luis Alcalá - Infectious Diseases

Author Information

Luís Alcalá is a prominent researcher in the field of Infectious Diseases, affiliated with the Department of Clinical Microbiology and Infectious Diseases at the Hospital General Universitario Gregorio Marañón in Madrid, Spain. He is also associated with the Instituto de Investigación Sanitaria Gregorio Marañón and the CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), both based in Madrid, Spain. His work primarily focuses on the study of infectious diseases, with a significant emphasis on the clinical microbiology aspects of pathogens and their impact on human health.

Research Contributions

Luís Alcalá has made substantial contributions to the understanding and management of infectious diseases, particularly during the ongoing COVID-19 pandemic. His research includes studies on post-COVID-19 syndrome, detection of SARS-CoV-2 in various biological samples, and the performance of antigen detection devices. He has also explored the genetic mutations associated with antifungal resistance in Candida glabrata and the role of biofilm production in Cutibacterium acnes. His work on the importation and transmission of SARS-CoV-2 variants further reflects his involvement in tracking and understanding viral dynamics during the pandemic.

Aliases

Luís Alcalá is known by several aliases, including Luis Alcalá, L. Alcalá, Luis Alcala, L. Alcala, and L Alcalá. These variations are often used interchangeably in academic publications and databases.

Publication and Citation Metrics

Metric	Value
Number of Papers	171
Citation Count	4,474
H-index	37

Publications:

Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19

DOI: 10.1186/s12879-022-07153-4

Year: 2022

Different performance of three point-of-care SARS-CoV-2 antigen detection devices in symptomatic patients and close asymptomatic contacts: a real-life study

DOI: 10.1016/j.cmi.2022.02.014

Year: 2022

ΔF659 and F659S substitutions at the HS1 of FKS2 gene, along with E655A and W715L upstream and downstream substitutions, correlate with high ibrexafungerp MICs against Candida glabrata.

DOI: 10.1016/j.cmi.2022.04.003

Year: 2022

Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience.

DOI: 10.37201/req/120.2021

Year: 2022

High incidence of COVID-19 at nursing homes in Madrid, Spain, despite preventive measures.

DOI: 10.37201/req/008.2022

Year: 2022

SARS‐CoV‐2 superinfection and reinfection with three different strains

DOI: 10.1111/tbed.14352

Year: 2021

SARS-CoV-2 superinfection and reinfection with three different strains

DOI: 10.22541/AU.162272385.53034671/V1

Year: 2021

SARS-CoV-2 B.1.1.7 Decline Is Not Driven by the Introduction of a More Successful Variant

DOI: 10.1128/Spectrum.01128-21

Year: 2021

First importations of SARS-CoV-2 P.1 and P.2 variants from Brazil to Spain and early community transmission

DOI: 10.1016/j.eimc.2021.05.008

Year: 2021

The role of biofilm production in Cutibacterium acnes strains isolated from breast implants.

DOI: 10.1016/j.bjps.2021.08.014

Year: 2021

What are the Treatment Options for Strep Throat?

What is a Biopsy?

What Role Do Viruses Play in Infectious Diseases?

When Should Antivirals Be Administered?

What Are the Challenges in Epigenetic Research Related to Infectious Diseases?

How Effective Are Condoms in Preventing HIV?

What are the main challenges in diagnosing Infectious Diseases?

What Treatment Options are Available?

What are the Strengths and Limitations?

How is Herpes Transmitted?

Partnered Content Networks

Relevant Topics